Abstract
A series of 3-benzoyl imidazo[1,2-a]pyrimidines,obtained from N-heteroarylformamidinesin good yields,was tested in silico and in vitro for binding and inhibition of seven Candidaspecies(Candida albicans(ATCC 10231),Candida dubliniensis(CD36),Candida glabrata(CBS138),Candida guilliermondii(ATCC 6260),Candida kefyr,Candida krusei(ATCC 6358)and Candida tropicalis(MYA-3404)).To predict binding mode and energy,each compound was docked in the active siteof the lanosterol 14α-demethylase enzyme(CYP51),essential for fungal growth of Candida species.Antimycotic activity was evaluated as the 50% minimum inhibitory concentration(MIC_(50))forthe test compounds and two reference drugs,ketoconazole and fluconazole.All test compoundshad a better binding energy(range:-6.11 to-9.43 kcal/mol)than that found for the referencedrugs(range:48.93 to-6.16 kcal/mol).In general,the test compounds showed greater inhibitoryactivity of yeast growth than the reference drugs.Compounds 4j and 4f were the most active,indicating an important role in biological activity for the benzene ring with electron-withdrawingsubstituents.These compounds show the best MIC_(50)against C.guilliermondii and C.glabrata,respectively.The current findings suggest that the 3-benzoyl imidazo[1,2-a]pyrimidine derivatives,herein synthesized by an accessible methodology,are potential antifungal drugs.
NSTL
Mdpi